LABx Corp. bolsters its product lineup with a new antigen test called the FINA Ag. Perfect for early detection of the presence of the SARS-CoV-2 virus in subjects, the FINA Ag boasts of short turnaround time, thanks to its easy-to-use kit. As far as accuracy is concerned, its sensitivity of 96% and specificity 98% means that the number of false positive and false negative results are extremely low. 

Antigen tests are becoming a viable option for point-of-care testing because they can be conducted rapidly and relatively cheaply, making them suitable for large communities. 

The FINA Ag is the second antigen test in the LABx roster, the other one being the Quidel Sofia 2.